Also found in: Wikipedia.
XLHX-linked Hypophosphatemia
XLHX Linked Hydrocephalus (genetic disorder)
XLHX-Linked Hypogammaglobulinaemia (genetic disorder)
XLHHarley-Davidson Sportster motorcycle model
References in periodicals archive ?
According to the company, Crysvita (burosumab-twza) is the first drug approved to treat adults and children ages one year and older with x-linked hypophosphatemia (XLH).
"XLH differs from other forms of rickets in that vitamin D therapy is not effective," Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in an agency news release.
XLH ADHR Prevalence 1 in 20,000 Rare individuals Serum phosphorous Low Low Serum calcium Normal Normal 1,25[(OH).sub.2]D3 Normal/low Normal/low PTH Normal/high Normal TmP/GFR Decreased Decreased Urine calcium Normal Normal Dental defect Dentine defects, Dental abscesses dental abscesses Muscle weakness Minimal Present Inheritance X-linked dominant Autosomal dominant Penetrance Complete with Incomplete, delayed variable expression.
X-linked hypophosphataemic rickets (XLH), which is the commonest of the hypophosphataemic syndromes, is caused by inactivating mutations in the PHEX gene, which result in elevations of FGF23.
Excessive paraneoplastic production of phosphatonin is thought to be involved in the etiology of tumor-induced osteomalacia, whereas impaired degradation and processing of phosphatonin due to endopeptidase mutations (PHEX gene: phosphate-regulating gene with homologies to endopeptidases on the X chromosome) is thought to cause the typical findings in XLH. The fibroblast growth factor (FGF)-23 gene is associated with ADHR.
Bone mineral density of the spine and radius shaft in children with X-linked hypophosphatemie rickets (XLH).
"Using State Consumer Tax Credits for Achieving Equity," National Tax Journal, XLH, 3, 1989, pp.
Sangermani Corvi, 1702), Dissertatio XLH (De impossibili et ente rationis), Sect.
Public healthcare company The US Food and Drug Administration stated on Tuesday that it has approved the first drug Crysvita (burosumab) for the treatment of adults and children ages one year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets.
X-linked Hypophosphataemia (XLH); is the most common heritable form of rickets in developed countries, accounting for 80% of HVDRR cases.
Prototype disorders are X linked hypophosphataemic rickets/osteomalacia (XLH), autosomal dominant hypophosphataemic rickets/osteomalacia (ADHR) and tumour induced hypophosphataemic rickets/ osteomalacia (TIO).
"Patients now have an approved breakthrough therapy that can help correct the underlying disease, transforming the treatment of XLH and reducing related bone disease in both children and adults living with this disease," said Emil D.